Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.79 |
| ▸ | PDGFRA | P16234 | 12/20 | 0.79 |
| ▸ | AXL | P30530 | 4/20 | 0.79 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.79 |
| ▸ | KIT | P10721 | 1/20 | 0.79 |
| ▸ | MET | P08581 | 3/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | TEK | Q02763 | 1/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5202090 | 0.92 | KDR (0.76) | KDRPDGFRAAXLFGFR2KIT | |
| SCHEMBL1896412 | 0.92 | KDR (0.67) | KDRPDGFRAAXLFGFR2KIT | |
| SCHEMBL1901501 | 0.92 | KDR (0.67) | KDRPDGFRAAXLFGFR2KIT | |
| SCHEMBL1249688 | 0.91 | KDR (0.66) | KDRPDGFRAAXLFGFR2KIT | |
| SCHEMBL5205551 | 0.91 | KDR (0.73) | KDRPDGFRAAXLFGFR2KIT | |
| SCHEMBL5205758 | 0.90 | PDGFRA (0.76) | KDRPDGFRAAXLFGFR2KIT | |
| SCHEMBL5207486 | 0.90 | KDR (0.75) | KDRPDGFRAAXLFGFR2KIT | |
| SCHEMBL5208828 | 0.90 | KDR (0.75) | KDRPDGFRAAXLFGFR2KIT | |
| SCHEMBL1889665 | 0.89 | KDR (0.64) | KDRPDGFRAAXLFGFR2KIT | |
| SCHEMBL5208189 | 0.89 | KDR (0.73) | KDRPDGFRAAXLFGFR2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1384712-B1 | Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity | KIRIN BREWERY (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-20070027318-A1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-02-01 | — | — | US | disclosed |
| US-7169789-B2 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-01-30 | — | — | US | disclosed |
| US-20040209905-A1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-10-21 | — | — | US | disclosed |
| US-6797823-B1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-09-28 | — | — | US | disclosed |
| EP-1384712-A1 | Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-01-28 | — | — | EP | disclosed |
| EP-1153920-B1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES | KIRIN BREWERY (JP) | 2003-10-29 | — | — | EP | disclosed |
| EP-1153920-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES | KIRIN BEER KABUSHIKI KAISHA (JP) | 2001-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027318-A1 | Quinoline derivatives and quinazoline derivatives | CYTH3, NQO2, NRAS | KDR 2466/4885PDGFRA 3108/4885AXL 1315/4885 |
| US-20040209905-A1 | Quinoline derivatives and quinazoline derivatives | RABL3, NRAS, CYTH3 | KDR 3106/4885PDGFRA 3103/4885AXL 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.